Pura Vida Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History

Pura Vida Investments’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-65,400	Closed	-$15.5M	–	78
2022 Q4	$15.5M	Buy	+65,400	New	+$13.9M	0.8%	32
2022 Q3	–	Sell	-25,300	Closed	-$3.69M	–	202
2022 Q2	$3.69M	Buy	25,300 +13,000	+106%	+$1.84M	0.21%	107
2022 Q1	$2.01M	Buy	+12,300	New	+$1.87M	0.07%	160

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Pura Vida Investments's ALNY Position: Q3 2022 in Review

Pura Vida Investments sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2022, closing a stake of 95,240 shares — an estimated $13.9M sold.

Pura Vida Investments first reported a position in ALNY in Q3 2016 and held it in 2 quarters. The position peaked at $13.9M in Q2 2022. 497 funds tracked by Wall St. Rank hold ALNY as of Q3 2022.

Pura Vida Investments reported no remaining Alnylam Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Pura Vida Investments sold 95,240 Alnylam Pharmaceuticals shares in Q3 2022, an estimated $13.9M.
Pura Vida Investments first reported a position in Alnylam Pharmaceuticals in Q3 2016 and held it in 2 quarters.
Pura Vida Investments's Alnylam Pharmaceuticals position peaked at $13.9M in Q2 2022.
497 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2022.

Based on Pura Vida Investments's 13F filing for Q3 2022, filed 14 Nov 2022.